Peter A White

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5289895/publications.pdf

Version: 2024-02-01

135 papers	10,084 citations	41344 49 h-index	36028 97 g-index
145 all docs	145 docs citations	145 times ranked	8879 citing authors

#	Article	IF	Citations
1	Novel viruses discovered in the transcriptomes of agnathan fish. Journal of Fish Diseases, 2022, 45, 931-938.	1.9	3
2	Viral fossils in marsupial genomes: secret cellular guardians. Microbiology Australia, 2021, 42, 134.	0.4	0
3	Nuclear localisation of West Nile virus NS5 protein modulates host gene expression. Virology, 2021, 559, 131-144.	2.4	5
4	Ancient viral integrations in marsupials: a potential antiviral defence. Virus Evolution, 2021, 7, veab076.	4.9	7
5	Discovery of Novel Viruses Associated With the Invasive Cane Toad (Rhinella marina) in Its Native and Introduced Ranges. Frontiers in Microbiology, 2021, 12, 733631.	3.5	7
6	Feline Calicivirus Virulent Systemic Disease: Clinical Epidemiology, Analysis of Viral Isolates and In Vitro Efficacy of Novel Antivirals in Australian Outbreaks. Viruses, 2021, 13, 2040.	3.3	14
7	Identification of Estrogen Receptor Modulators as Inhibitors of Flavivirus Infection. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	23
8	Novel insights into endogenous RNA viral elements in Ixodes scapularis and other arbovirus vector genomes. Virus Evolution, 2019, 5, vez010.	4.9	34
9	The Microtubule-Associated Innate Immune Sensor GEF-H1 Does Not Influence Mouse Norovirus Replication in Murine Macrophages. Viruses, 2019, 11, 47.	3.3	4
10	Mouse Norovirus Infection Arrests Host Cell Translation Uncoupled from the Stress Granule-PKR-eIF2Î± Axis. MBio, 2019, 10, .	4.1	39
11	The Adenosine Analogue NITD008 has Potent Antiviral Activity against Human and Animal Caliciviruses. Viruses, 2019, 11, 496.	3.3	8
12	Genetic diversity and quantification of human mastadenoviruses in wastewater from Sydney and Melbourne, Australia. Science of the Total Environment, 2019, 675, 305-312.	8.0	16
13	Antiviral Candidates for Treating Hepatitis E Virus Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	41
14	Norovirus antivirals: Where are we now?. Medicinal Research Reviews, 2019, 39, 860-886.	10.5	50
15	Detection of norovirus epidemic genotypes in raw sewage using next generation sequencing. Environment International, 2019, 123, 282-291.	10.0	65
16	Updated classification of norovirus genogroups and genotypes. Journal of General Virology, 2019, 100, 1393-1406.	2.9	535
17	ICTV Virus Taxonomy Profile: Caliciviridae. Journal of General Virology, 2019, 100, 1469-1470.	2.9	117
18	In silico screening for human norovirus antivirals reveals a novel non-nucleoside inhibitor of the viral polymerase. Scientific Reports, 2018, 8, 4129.	3.3	24

#	Article	IF	Citations
19	Gastroenteritis outbreak at a health function caused by an emerging recombinant strain of Norovirus GII.P16/GII.4 Sydney 2012, Australia. Epidemiology and Infection, 2018, 146, 970-971.	2.1	4
20	Nucleocytoplasmic shuttling of the West Nile virus <scp>RNA</scp> â€dependent <scp>RNA</scp> polymerase <scp>NS5</scp> is critical to infection. Cellular Microbiology, 2018, 20, e12848.	2.1	33
21	TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
22	Recombinant GII.P16/GII.4 Sydney 2012 Was the Dominant Norovirus Identified in Australia and New Zealand in 2017. Viruses, 2018, 10, 548.	3.3	37
23	Draft genome assembly of the invasive cane toad, Rhinella marina. GigaScience, 2018, 7, .	6.4	60
24	Mouse Norovirus Infection Reduces the Surface Expression of Major Histocompatibility Complex Class I Proteins and Inhibits CD8 ⁺ T Cell Recognition and Activation. Journal of Virology, 2018, 92, .	3.4	9
25	Emerging recombinant noroviruses identified by clinical and waste water screening. Emerging Microbes and Infections, 2018, 7, 1-14.	6.5	41
26	Potential Therapeutic Agents for Feline Calicivirus Infection. Viruses, 2018, 10, 433.	3.3	18
27	Viral Discovery in the Invasive Australian Cane Toad (Rhinella marina) Using Metatranscriptomic and Genomic Approaches. Journal of Virology, 2018, 92, .	3.4	13
28	Broad-spectrum non-nucleoside inhibitors for caliciviruses. Antiviral Research, 2017, 146, 65-75.	4.1	17
29	The Norovirus NS3 Protein Is a Dynamic Lipid- and Microtubule-Associated Protein Involved in Viral RNA Replication. Journal of Virology, 2017, 91, .	3.4	26
30	A Motif in the F Homomorph of Rabbit Haemorrhagic Disease Virus Polymerase Is Important for the Subcellular Localisation of the Protein and Its Ability to Induce Redistribution of Golgi Membranes. Viruses, 2017, 9, 202.	3.3	7
31	RNA Sequencing of Murine Norovirus-Infected Cells Reveals Transcriptional Alteration of Genes Important to Viral Recognition and Antigen Presentation. Frontiers in Immunology, 2017, 8, 959.	4.8	17
32	Persistent infections in immunocompromised hosts are rarely sources of new pathogen variants. Virus Evolution, 2017, 3, vex018.	4.9	21
33	Global Spread of Norovirus GII.17 Kawasaki 308, 2014â€“2016. Emerging Infectious Diseases, 2017, 23, 1359-1354.	4.3	71
34	Membrane alterations induced by nonstructural proteins of human norovirus. PLoS Pathogens, 2017, 13, e1006705.	4.7	64
35	Norovirus and cruise ships. Microbiology Australia, 2017, 38, 187.	0.4	2
36	Purification and Biochemical Characterisation of Rabbit Calicivirus RNA-Dependent RNA Polymerases and Identification of Non-Nucleoside Inhibitors. Viruses, 2016, 8, 100.	3.3	21

#	Article	IF	Citations
37	Ancient recombination events and the origins of hepatitis E virus. BMC Evolutionary Biology, 2016, 16, 210.	3.2	31
38	A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014. PLoS ONE, 2016, 11, e0145254.	2.5	27
39	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS ONE, 2016, 11, e0150655.	2.5	15
40	8th Australasian Virology Society Meeting. Microbiology Australia, 2016, 37, 99.	0.4	0
41	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses, 2015, 7, 5206-5224.	3.3	102
42	Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection. PLoS ONE, 2015, 10, e0126397.	2.5	6
43	Detection and molecular characterization of caliciviruses (vesivirus and norovirus) in an outbreak of acute diarrhea in kittens from Brazil. Veterinary Journal, 2015, 206, 115-117.	1.7	10
44	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005â€“2012. Emerging Infectious Diseases, 2015, 21, 765-774.	4.3	37
45	Treatment of norovirus particles with citrate. Virology, 2015, 485, 199-204.	2.4	42
46	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	3.3	44
47	Evidence that hepatitis C virus genome partly controls infection outcome. Evolutionary Applications, 2014, 7, 533-547.	3.1	4
48	Viral niche construction alters hosts and ecosystems at multiple scales. Trends in Ecology and Evolution, 2014, 29, 594-599.	8.7	15
49	Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders. Antimicrobial Agents and Chemotherapy, 2014, 58, 7215-7224.	3.2	12
50	Evolution of norovirus. Clinical Microbiology and Infection, 2014, 20, 741-745.	6.0	125
51	Nonnucleoside Inhibitors of Norovirus RNA Polymerase: Scaffolds for Rational Drug Design. Antimicrobial Agents and Chemotherapy, 2014, 58, 3115-3123.	3.2	41
52	The emergence and evolution of the novel epidemic norovirus GII.4 variant Sydney 2012. Virology, 2014, 450-451, 106-113.	2.4	111
53	Molecular epidemiology of norovirus in Singapore, 2004-2011. Journal of Medical Virology, 2013, 85, 1842-1851.	5.0	19
54	Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a twoâ€centre, masked, caseâ€control study. Journal of Viral Hepatitis, 2013, 20, 725-728.	2.0	9

#	Article	IF	Citations
55	Proposal for a unified norovirus nomenclature and genotyping. Archives of Virology, 2013, 158, 2059-2068.	2.1	488
56	A Fluorescence-Based High-Throughput Screen to Identify Small Compound Inhibitors of the Genotype 3a Hepatitis C Virus RNA Polymerase. Journal of Biomolecular Screening, 2013, 18, 1027-1034.	2.6	28
57	Maintenance of <scp>T</scp>h1 hepatitis <scp>C</scp> virus (<scp>HCV)</scp>â€specific responses in individuals with acute <scp>HCV</scp> who achieve sustained virological clearance after treatment. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1770-1781.	2.8	17
58	Recombination within the Pandemic Norovirus GII.4 Lineage. Journal of Virology, 2013, 87, 6270-6282.	3.4	239
59	Hepatitis C Virus Nonstructural Protein 5B Is Involved in Virus Morphogenesis. Journal of Virology, 2012, 86, 5080-5088.	3.4	35
60	Impaired Hepatitis C Virus (HCV)â€“Specific Interferon-Î³ Responses in Individuals With HIV Who Acquire HCV Infection: Correlation With CD4+ T-Cell Counts. Journal of Infectious Diseases, 2012, 206, 1568-1576.	4.0	21
61	Complete Genome of the Human Norovirus GIV.1 Strain Lake Macquarie Virus. Journal of Virology, 2012, 86, 10251-10252.	3.4	14
62	Molecular epidemiology of noroviruses and sapoviruses and their role in Australian outbreaks of acute gastroenteritis. Microbiology Australia, 2012, 33, 70.	0.4	5
63	Contribution of Intra- and Interhost Dynamics to Norovirus Evolution. Journal of Virology, 2012, 86, 3219-3229.	3.4	109
64	Occult infection with hepatitis C virus: friend or foe?. Immunology and Cell Biology, 2012, 90, 763-773.	2.3	13
65	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology, 2012, 55, 1058-1069.	7.3	82
66	Effect of pegylated interferonâ€Î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	2.8	38
67	Transmission of hepatitis C virus to recipients of parenteral vitamin therapy in a primary care facility. Journal of Clinical Virology, 2011, 51, 105-109.	3.1	2
68	Mechanisms of GII.4 norovirus evolution. Trends in Microbiology, 2011, 19, 233-240.	7.7	135
69	Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. Journal of Viral Hepatitis, 2011, 18, 549-561.	2.0	54
70	Evaluation of the biological efficacy of hydrogen peroxide vapour decontamination in wards of an Australian hospital. Journal of Hospital Infection, 2011, 79, 125-128.	2.9	26
71	Comparison of the replication properties of murine and human calicivirus RNA-dependent RNA polymerases. Virus Genes, 2011, 42, 16-27.	1.6	26
72	Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases, 2011, 52, 803-811.	5.8	95

#	Article	IF	Citations
73	Norovirus RNA-Dependent RNA Polymerase Is Phosphorylated by an Important Survival Kinase, Akt. Journal of Virology, 2011, 85, 10894-10898.	3.4	22
74	Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection. PLoS Pathogens, 2011, 7, e1002243.	4.7	201
75	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52, 1216-1224.	7.3	156
76	Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology, 2010, 52, 1564-1572.	7.3	88
77	Transmission of tripleâ€class, drugâ€resistant HIVâ€1 in Australia. Internal Medicine Journal, 2010, 40, 657-661.	0.8	2
78	Evolution of AbaR-type genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2010, 65, 1162-1170.	3.0	149
79	Rapid Evolution of Pandemic Noroviruses of the GII.4 Lineage. PLoS Pathogens, 2010, 6, e1000831.	4.7	252
80	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 123-135.e2.	1.3	157
81	Norovirus GII.4 variant 2006b caused epidemics of acute gastroenteritis in Australia during 2007 and 2008. Journal of Clinical Virology, 2010, 49, 265-271.	3.1	77
82	Viral Genotyping and the Sequencing Revolution. Infectious Disease and Therapy, 2010, , 40-58.	0.0	0
83	Norovirus Illness Is a Global Problem: Emergence and Spread of Norovirus GII.4 Variants, 2001â€“2007. Journal of Infectious Diseases, 2009, 200, 802-812.	4.0	596
84	Multiplex PCR Testing Detection of Higher-than-Expected Rates of Cervical Mycoplasma , Ureaplasma , and Trichomonas and Viral Agent Infections in Sexually Active Australian Women. Journal of Clinical Microbiology, 2009, 47, 1358-1363.	3.9	66
85	Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2009, 63, 47-54.	3.0	130
86	Characteristics and Treatment Outcomes among HIVâ€Infected Individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases, 2009, 48, 650-658.	5.8	109
87	Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men. Gastroenterology, 2009, 136, 1609-1617.	1.3	285
88	Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study. Canadian Journal of Addiction, 2009, 1, 33.	0.4	0
89	810 FREQUENCY OF RVR AND ITS UTILITY AS A PREDICTOR OF TREATMENT OUTCOME IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C (ATAHC). Journal of Hepatology, 2008, 48, S303.	3.7	0
90	Multidrug-Resistant Salmonella Strains Expressing Emerging Antibiotic Resistance Determinants. Clinical Infectious Diseases, 2008, 46, 324-325.	5.8	26

#	Article	IF	Citations
91	Norovirus Excretion in an Aged-Care Setting. Journal of Clinical Microbiology, 2008, 46, 2119-2121.	3.9	83
92	Epidemics of Gastroenteritis during 2006 Were Associated with the Spread of Norovirus GII.4 Variants 2006a and 2006b. Clinical Infectious Diseases, 2008, 46, 413-420.	5.8	152
93	Norovirus recombination. Journal of General Virology, 2007, 88, 3347-3359.	2.9	294
94	Norovirus GII.4 Strains and Outbreaks, Australia. Emerging Infectious Diseases, 2007, 13, 1128-1130.	4.3	80
95	High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. Journal of Viral Hepatitis, 2007, 14, 413-418.	2.0	95
96	Preservation of micro-organisms by drying; A review. Journal of Microbiological Methods, 2006, 66, 183-193.	1.6	489
97	Genetic Diversity of Sapovirus in Children, Australia. Emerging Infectious Diseases, 2006, 12, 141-143.	4.3	33
98	Detection of human sapovirus by real-time reverse transcription-polymerase chain reaction. Journal of Medical Virology, 2006, 78, 1347-1353.	5.0	228
99	High-Affinity Aptamers to Subtype 3a Hepatitis C Virus Polymerase Display Genotypic Specificity. Antimicrobial Agents and Chemotherapy, 2006, 50, 3019-3027.	3.2	45
100	Emergence of a New Norovirus Genotype II.4 Variant Associated with Global Outbreaks of Gastroenteritis. Journal of Clinical Microbiology, 2006, 44, 327-333.	3.9	302
101	Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. Journal of Viral Hepatitis, 2005, 12, 322-324.	2.0	32
102	Human enterovirus isolates from an outbreak typed using heteroduplex mobility analysis. Journal of Medical Virology, 2005, 76, 215-222.	5.0	4
103	Norovirus Recombination in ORF1/ORF2 Overlap. Emerging Infectious Diseases, 2005, 11, 1079-1085.	4.3	257
104	The aadB Gene Cassette Is Associated with bla SHV Genes in Klebsiella Species Producing Extended-Spectrum Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2005, 49, 794-797.	3.2	27
105	In Vitro Assessment of the Further Potential for Development of Fluoroquinolone Resistance in Neisseria meningitidis. Antimicrobial Agents and Chemotherapy, 2005, 49, 1753-1760.	3.2	25
106	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases, 2004, 189, 1846-1855.	4.0	147
107	Prevalence of Production of Virusâ€Specific Interferonâ€Î³ among Seronegative Hepatitis Câ€“Resistant Subjects Reporting Injection Drug Use. Journal of Infectious Diseases, 2004, 190, 1093-1097.	4.0	51
108	Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations. Pathology, 2004, 36, 166-169.	0.6	17

#	Article	IF	Citations
109	Clearance of Hepatitis C Virus after Newly Acquired Infection in Injection Drug Users. Journal of Infectious Diseases, 2004, 190, 1270-1274.	4.0	65
110	Production of precise microbiology standards using flow cytometry and freeze drying. Cytometry, 2004, 62A, 162-168.	1.8	16
111	The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. Journal of Hepatology, 2003, 38, 349-356.	3.7	64
112	Chloramphenicol-resistant Neisseria meningitidis containing catP isolated in Australia. Journal of Antimicrobial Chemotherapy, 2003, 52, 856-859.	3.0	35
113	Epidemic Strains of Shigella sonnei Biotype g Carrying Integrons. Journal of Clinical Microbiology, 2002, 40, 1538-1540.	3.9	51
114	Quantification of Hepatitis C Virus in Human Liver and Serum Samples by Using LightCycler Reverse Transcriptase PCR. Journal of Clinical Microbiology, 2002, 40, 4346-4348.	3.9	45
115	Norwalk-like virus 95/96-US strain is a major cause of gastroenteritis outbreaks in Australia. Journal of Medical Virology, 2002, 68, 113-118.	5.0	73
116	Integrons and Gene Cassettes in the Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2001, 45, 2658-2661.	3.2	406
117	Diagnosis of enteric pathogens in children with gastroenteritis. Pathology, 2001, 33, 353-358.	0.6	49
118	Current status of the aadA and dfr gene cassette families. Journal of Antimicrobial Chemotherapy, 2001, 47, 495-496.	3.0	46
119	Correlation of In Vitro Susceptibilities to Newer Quinolones of Naturally Occurring Quinolone-Resistant Neisseria gonorrhoeae Strains with Changes in GyrA and ParC. Antimicrobial Agents and Chemotherapy, 2001, 45, 734-738.	3.2	65
120	DIAGNOSIS OF ENTERIC PATHOGENS IN CHILDREN WITH GASTROENTERITIS. Pathology, 2001, 33, 353-358.	0.6	4
121	Human cytomegalovirus strains associated with congenital and perinatal infections. Journal of Medical Virology, 2000, 61, 481-487.	5.0	94
122	Characterisation of two new gene cassettes,aadA5anddfrA17. FEMS Microbiology Letters, 2000, 182, 265-269.	1.8	169
123	Mixed Viral Infection Identified Using Heteroduplex Mobility Analysis (HMA). Virology, 2000, 271, 382-389.	2.4	43
124	An Invasive Isolate of Neisseria meningitidis Showing Decreased Susceptibility to Quinolones. Antimicrobial Agents and Chemotherapy, 2000, 44, 1116-1116.	3.2	42
125	Characterisation of two new gene cassettes, aadA5 and dfrA17. FEMS Microbiology Letters, 2000, 182, 265-269.	1.8	8
126	Simplified Hepatitis C Virus Genotyping by Heteroduplex Mobility Analysis. Journal of Clinical Microbiology, 2000, 38, 477-482.	3.9	79

#	Article	IF	Citations
127	Transmission of hepatitis C within Australian prisons. Medical Journal of Australia, 1999, 171, 31-33.	1.7	51
128	Characterisation of a chloramphenicol acetyltransferase determinant found in the chromosome ofPseudomonas aeruginosa. FEMS Microbiology Letters, 1999, 175, 27-35.	1.8	41
129	Sequence diversity in the 5â€²-UTR region of GB virus C/hepatitis G virus assessed using sequencing, heteroduplex mobility analysis and single-strand conformation polymorphism. Journal of Virological Methods, 1999, 83, 91-101.	2.1	10
130	Control of the human cell cycle by a bacterial protein, gapstatin. European Journal of Cell Biology, 1998, 77, 228-238.	3.6	14
131	Molecular Characterization of an Outer Membrane Protein of Actinobacillus actinomycetemcomitans Belonging to the OmpA Family. Infection and Immunity, 1998, 66, 369-372.	2.2	24
132	Mycobacterium tuberculosis Chaperonin 10 Stimulates Bone Resorption: A Potential Contributory Factor in Pott's Disease. Journal of Experimental Medicine, 1997, 186, 1241-1246.	8.5	89
133	Surface-Associated Material from the Bacterium Actinobacillus actinomycetemcomitans Contains A Peptide Which, in Contrast to Lipopolysaccharide, Directly Stimulates Fibroblast Interleukin-6 Gene Transcription. FEBS Journal, 1996, 236, 871-876.	0.2	37
134	Characterization of an antiproliferative surface-associated protein from Actinobacillus actinomycetemcomitans which can be neutralized by sera from a proportion of patients with localized juvenile periodontitis. Infection and Immunity, 1995, 63, 2612-2618.	2.2	44
135	The potent bone-resorbing mediator of Actinobacillus actinomycetemcomitans is homologous to the molecular chaperone GroEL.. Journal of Clinical Investigation, 1995, 96, 1185-1194.	8.2	125